Cabaletta Bio (CABA): Assessing Valuation After Promising Clinical Trial Results and Growing Investor Interest [Yahoo! Finance]
Cabaletta Bio, Inc. (CABA)
Company Research
Source: Yahoo! Finance
Presentations at the American College of Rheumatology Convergence showcased their progress and prepared the company for key regulatory updates. See our latest analysis for Cabaletta Bio. All this news comes on the heels of a remarkable run for Cabaletta Bio's share price, which climbed 86% over the last 90 days, clearly reflecting growing excitement as clinical and business milestones stack up. Even with a 36% decrease in total shareholder return over the past year, recent momentum hints at renewed optimism and shifting risk perceptions following the company's strong data presentations and expansion of investor outreach. If Cabaletta's recent surge caught your attention, now is a smart time to see what other healthcare innovators are making waves — See the full list for free. After such an impressive rally, investors are now left to wonder whether Cabaletta Bio's current valuation still offers upside or if the market has already factored in all the company's potential growth.
Show less
Read more
Impact Snapshot
Event Time:
CABA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CABA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CABA alerts
High impacting Cabaletta Bio, Inc. news events
Weekly update
A roundup of the hottest topics
CABA
News
- Cabaletta Bio Reports Third Quarter 2025 Financial Results and Provides Business Update [Yahoo! Finance]Yahoo! Finance
- Cabaletta Bio GAAP EPS of -$0.44 beats by $0.04 [Seeking Alpha]Seeking Alpha
- Cabaletta Bio Reports Third Quarter 2025 Financial Results and Provides Business UpdateGlobeNewswire
- Cabaletta Bio to Participate in Upcoming Investor Conferences in November and DecemberGlobeNewswire
- Cabaletta Bio (NASDAQ:CABA) had its price target raised by analysts at Cantor Fitzgerald from $15.00 to $30.00. They now have an "overweight" rating on the stock.MarketBeat
CABA
Earnings
- 11/10/25 - Beat
CABA
Sec Filings
- 11/14/25 - Form SCHEDULE
- 11/14/25 - Form SCHEDULE
- 11/14/25 - Form SCHEDULE
- CABA's page on the SEC website